Logo

American Heart Association

  19
  0


Final ID: MP2326

Cardiovascular Diagnoses Following Smartwatch Irregular Pulse Notifications: Insights from the Apple Heart Study

Abstract Body (Do not enter title and authors here): Background
Atrial fibrillation (AF) is a leading cause of cardiovascular morbidity and mortality, and early detection is important for stroke prevention. The Apple Heart Study (AHS) demonstrated that wearable devices capable of irregular pulse notifications (IPN) can aid in identifying AF. The rates of subsequent diagnoses of cardiovascular disease (CVD) remain unknown.

Hypothesis
We aimed to evaluate how smartwatch-detected IPNs are associated with key cardiovascular diagnoses. We hypothesized that, among AHS participants, receiving IPNs would be associated with increased odds of subsequently reporting major cardiovascular diagnoses compared to participants without IPNs.

Methods
Out of 419,297 enrolled AHS participants, 288,533 (69%) individuals who completed the end-of-study survey (EOS) were included in this analysis. The self-reported diagnoses consisted of heart failure (HF), stroke, transient ischemic attack (TIA), myocardial infarction (MI), and pulmonary embolism (PE), considered individually and as a composite (MACE). Logistic regression was used to estimate odds ratios (ORs) for each diagnosis among IPN versus non-IPN participants, adjusted for sex, age, and CHA2DS2-VASc components.

Results
The EOS survey was completed by 908 notified participants (42% among the IPN cohort) and 287,625 non-notified participants (69% among the non-IPN cohort). IPN recipients were older, more often male, and had a higher comorbidity burden and CVD risk factors than the total cohort (Table 1). The IPN cohort reported higher rates of HF, MI, stroke, TIA, and PE compared to those who did not receive an IPN (Table 2). The fully adjusted logistic regression analysis showed increased odds of each diagnosis among the IPN group (Figure 1).

Conclusions
Participants with an IPN had higher odds of subsequently reporting major adverse cardiovascular diagnoses. These associations may reflect pre-existing conditions, underlying CVD risk, and comorbidities among participants who received an IPN, which has a high positive predictive value (PPV) for detecting AF. Given the elevated odds and high PPV, IPNs may warrant clinical consideration of evaluation for CVD or comorbidities, and future studies should assess the diagnostic and management pathways following IPNs.
  • Perez Guerrero, Eduardo  ( Stanford University , Stanford , California , United States )
  • Russo, Andrea  ( Cooper University Health Care , Moorestown , New Jersey , United States )
  • Granger, Christopher  ( DUKE CLINICAL RESEARCH INSTITUTE , Durham , North Carolina , United States )
  • Kowey, Peter  ( LANKENAU MEDICAL CENTER , Wynnewood , Pennsylvania , United States )
  • Hills, Mellanie  ( StopAfib.org , Greenwood , Texas , United States )
  • Rumsfeld, John  ( University of Colorado , Aurora , Colorado , United States )
  • Turakhia, Mintu  ( Stanford University , Palo Alto , California , United States )
  • Mahaffey, Kenneth  ( Stanford University , Stanford , California , United States )
  • Perez, Marco  ( STANFORD UNIV HOSPITAL , Stanford , California , United States )
  • Parsa, Shyon  ( Stanford University Hospital , Mountain View , California , United States )
  • Gjermeni, Diona  ( Stanford University , Stanford , California , United States )
  • Sakalaki, Maria  ( Stanford University , Stanford , California , United States )
  • Alipour, Pouria  ( University of Ottawa , Ottawa , Ontario , Canada )
  • Yu, Kevin  ( Stanford University , Stanford , California , United States )
  • Hedlin, Haley  ( Stanford University , Stanford , California , United States )
  • Desai, Manisha  ( Stanford University , Stanford , California , United States )
  • Phillips, Adam  ( Apple, Inc. , Cupertino , California , United States )
  • Author Disclosures:
    Eduardo Perez Guerrero: DO NOT have relevant financial relationships | Andrea Russo: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott, Bayer, Boston Scientific, Medtronic and Novartis:Active (exists now) ; Royalties/Patent Beneficiary:Royalties (writing/editing): UpToDate:Active (exists now) ; Other (please indicate in the box next to the company name):Fellowship support: Medtronic:Active (exists now) ; Consultant:Abbott, Atricure, Bayer, Sanofi:Past (completed) ; Consultant:Biosense Webster, Biotronik, Boston Scientific, Medtronic, Orchestra BioMed, PaceMate :Active (exists now) | Christopher Granger: DO have relevant financial relationships ; Consultant:Alnylam:Active (exists now) ; Consultant:Pfizer:Active (exists now) ; Researcher:Boehringer Ingelheim:Past (completed) ; Consultant:Anthos:Active (exists now) ; Researcher:Anthos:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Researcher:Phillips:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Celecor:Active (exists now) ; Consultant:Roche:Active (exists now) ; Researcher:Roche:Active (exists now) ; Researcher:Alnylam:Active (exists now) | Peter Kowey: DO NOT have relevant financial relationships | Mellanie Hills: DO have relevant financial relationships ; Employee:American Foundation for Women's Health:Active (exists now) ; Employee:True Hills, Inc:Active (exists now) | JOHN RUMSFELD: No Answer | Mintu Turakhia: No Answer | Kenneth Mahaffey: DO have relevant financial relationships ; Consultant:Applied Therapuetics:Past (completed) ; Consultant:NovoNordisk:Past (completed) ; Consultant:Novartis:Past (completed) ; Researcher:Novartis:Active (exists now) ; Researcher:Myovant:Past (completed) ; Consultant:Myokardia:Past (completed) ; Consultant:Moderna:Active (exists now) ; Individual Stocks/Stock Options:Medeloop - equity:Active (exists now) ; Researcher:Luitpold:Past (completed) ; Consultant:J&J:Past (completed) ; Researcher:J&J:Active (exists now) ; Research Funding (PI or named investigator):Idorsia:Active (exists now) ; Individual Stocks/Stock Options:Human - equity:Active (exists now) ; Research Funding (PI or named investigator):Verily:Active (exists now) ; Consultant:Fuson Pharma:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Element:Past (completed) ; Research Funding (PI or named investigator):Eidos:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Past (completed) ; Research Funding (PI or named investigator):CSL:Active (exists now) ; Consultant:BridgeBio:Active (exists now) ; Consultant:BMS:Past (completed) ; Researcher:Bayer:Active (exists now) ; Consultant:Bayer:Past (completed) ; Research Funding (PI or named investigator):Apple:Active (exists now) | Marco Perez: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH/NHLBI:Active (exists now) ; Ownership Interest:QALY Inc.:Active (exists now) ; Ownership Interest:Pacegenix:Active (exists now) ; Consultant:Pacegenix:Active (exists now) ; Consultant:Simplex Quantum:Active (exists now) ; Consultant:Thryv:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Johnson and Johnson:Active (exists now) ; Consultant:Apple Inc.:Active (exists now) ; Research Funding (PI or named investigator):Johnson and Johnson:Active (exists now) ; Research Funding (PI or named investigator):Lexeo Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Apple Inc.:Active (exists now) | Shyon Parsa: DO NOT have relevant financial relationships | Diona Gjermeni: DO NOT have relevant financial relationships | Maria Sakalaki: DO NOT have relevant financial relationships | Pouria Alipour: DO NOT have relevant financial relationships | Kevin Yu: No Answer | Haley Hedlin: DO NOT have relevant financial relationships | Manisha Desai: No Answer | Adam Phillips: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

AI & Digital Tools in CVD Research

Monday, 11/10/2025 , 10:45AM - 11:55AM

Moderated Digital Poster Session

More abstracts on this topic:
3-Minute Heart Health App: A Feasibility Study

Abdulkarim Iya, Metzger Joseph, Stovitz Steven, Van't Hof Jeremy

A dual probe ultrasound vector Doppler method for a robust and reliable estimation of blood flow volume and pulse wave velocity on the carotid artery

Mattesini Paolo, Ramalli Alessandro, Travagliati Marco, Confalonieri Federica, Baldasarre Leonardo

More abstracts from these authors:
Panelist

Russo Andrea

Discussant: DECAF

Russo Andrea

You have to be authorized to contact abstract author. Please, Login
Not Available